Molecular Profiling of Immunotherapeutic Resistance

Davide Bedognetti, Ena Wang, Marimo Sato-Matsushita, Francesco M. Marincola, Maria Libera Ascierto

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

During the last few years several immunotherapies have been shown to induce clinical response and/or improve the clinical outcome in a significant number of cancer patients. However, the lack of a human-centered translational approach has led to the accumulation of a multitude of disjointed clinical and basic researches with a consequent disharmonic growth of the scientific knowledge. The huge number of non-evidence-based conjectural hypotheses has competitively interacted with the few evidence-based hypotheses generated by studies conducted in humans leading to the accumulation of several clinical breakdowns and few "mysterious" successes.In the last decade, the availability of high-throughput gene expression profiling has led to the development of novel discovery-driven approaches capable of investigating the tumor/host integration in its globality. Here, we describe in detail gene expression profiling studies that have led to the formulation of a new generation of evidence-based hypotheses explaining the structural basis of the immune-mediated tumor rejection following immunotherapy.

Original languageEnglish
Title of host publicationCancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition
PublisherElsevier Inc.
Pages373-394
Number of pages22
ISBN (Print)9780123942968
DOIs
Publication statusPublished - Jul 2013
Externally publishedYes

Fingerprint

Gene Expression Profiling
Immunotherapy
Neoplasms
Growth
Research

Keywords

  • Adoptive therapy
  • Bedside to bench and back
  • Biomarker
  • CCR5
  • Chemokine
  • CXCR3
  • Gene expression profiling
  • Gene signature
  • High-throughput technology
  • Immunologic constant of rejection
  • Immunotherapy
  • Interferon signaling
  • Interleukin-2
  • Microarray
  • Vaccine therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Bedognetti, D., Wang, E., Sato-Matsushita, M., Marincola, F. M., & Ascierto, M. L. (2013). Molecular Profiling of Immunotherapeutic Resistance. In Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition (pp. 373-394). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-394296-8.00023-3

Molecular Profiling of Immunotherapeutic Resistance. / Bedognetti, Davide; Wang, Ena; Sato-Matsushita, Marimo; Marincola, Francesco M.; Ascierto, Maria Libera.

Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., 2013. p. 373-394.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bedognetti, D, Wang, E, Sato-Matsushita, M, Marincola, FM & Ascierto, ML 2013, Molecular Profiling of Immunotherapeutic Resistance. in Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., pp. 373-394. https://doi.org/10.1016/B978-0-12-394296-8.00023-3
Bedognetti D, Wang E, Sato-Matsushita M, Marincola FM, Ascierto ML. Molecular Profiling of Immunotherapeutic Resistance. In Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc. 2013. p. 373-394 https://doi.org/10.1016/B978-0-12-394296-8.00023-3
Bedognetti, Davide ; Wang, Ena ; Sato-Matsushita, Marimo ; Marincola, Francesco M. ; Ascierto, Maria Libera. / Molecular Profiling of Immunotherapeutic Resistance. Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. Elsevier Inc., 2013. pp. 373-394
@inbook{51d807048c23416c87fd38a2313e73a9,
title = "Molecular Profiling of Immunotherapeutic Resistance",
abstract = "During the last few years several immunotherapies have been shown to induce clinical response and/or improve the clinical outcome in a significant number of cancer patients. However, the lack of a human-centered translational approach has led to the accumulation of a multitude of disjointed clinical and basic researches with a consequent disharmonic growth of the scientific knowledge. The huge number of non-evidence-based conjectural hypotheses has competitively interacted with the few evidence-based hypotheses generated by studies conducted in humans leading to the accumulation of several clinical breakdowns and few {"}mysterious{"} successes.In the last decade, the availability of high-throughput gene expression profiling has led to the development of novel discovery-driven approaches capable of investigating the tumor/host integration in its globality. Here, we describe in detail gene expression profiling studies that have led to the formulation of a new generation of evidence-based hypotheses explaining the structural basis of the immune-mediated tumor rejection following immunotherapy.",
keywords = "Adoptive therapy, Bedside to bench and back, Biomarker, CCR5, Chemokine, CXCR3, Gene expression profiling, Gene signature, High-throughput technology, Immunologic constant of rejection, Immunotherapy, Interferon signaling, Interleukin-2, Microarray, Vaccine therapy",
author = "Davide Bedognetti and Ena Wang and Marimo Sato-Matsushita and Marincola, {Francesco M.} and Ascierto, {Maria Libera}",
year = "2013",
month = "7",
doi = "10.1016/B978-0-12-394296-8.00023-3",
language = "English",
isbn = "9780123942968",
pages = "373--394",
booktitle = "Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Molecular Profiling of Immunotherapeutic Resistance

AU - Bedognetti, Davide

AU - Wang, Ena

AU - Sato-Matsushita, Marimo

AU - Marincola, Francesco M.

AU - Ascierto, Maria Libera

PY - 2013/7

Y1 - 2013/7

N2 - During the last few years several immunotherapies have been shown to induce clinical response and/or improve the clinical outcome in a significant number of cancer patients. However, the lack of a human-centered translational approach has led to the accumulation of a multitude of disjointed clinical and basic researches with a consequent disharmonic growth of the scientific knowledge. The huge number of non-evidence-based conjectural hypotheses has competitively interacted with the few evidence-based hypotheses generated by studies conducted in humans leading to the accumulation of several clinical breakdowns and few "mysterious" successes.In the last decade, the availability of high-throughput gene expression profiling has led to the development of novel discovery-driven approaches capable of investigating the tumor/host integration in its globality. Here, we describe in detail gene expression profiling studies that have led to the formulation of a new generation of evidence-based hypotheses explaining the structural basis of the immune-mediated tumor rejection following immunotherapy.

AB - During the last few years several immunotherapies have been shown to induce clinical response and/or improve the clinical outcome in a significant number of cancer patients. However, the lack of a human-centered translational approach has led to the accumulation of a multitude of disjointed clinical and basic researches with a consequent disharmonic growth of the scientific knowledge. The huge number of non-evidence-based conjectural hypotheses has competitively interacted with the few evidence-based hypotheses generated by studies conducted in humans leading to the accumulation of several clinical breakdowns and few "mysterious" successes.In the last decade, the availability of high-throughput gene expression profiling has led to the development of novel discovery-driven approaches capable of investigating the tumor/host integration in its globality. Here, we describe in detail gene expression profiling studies that have led to the formulation of a new generation of evidence-based hypotheses explaining the structural basis of the immune-mediated tumor rejection following immunotherapy.

KW - Adoptive therapy

KW - Bedside to bench and back

KW - Biomarker

KW - CCR5

KW - Chemokine

KW - CXCR3

KW - Gene expression profiling

KW - Gene signature

KW - High-throughput technology

KW - Immunologic constant of rejection

KW - Immunotherapy

KW - Interferon signaling

KW - Interleukin-2

KW - Microarray

KW - Vaccine therapy

UR - http://www.scopus.com/inward/record.url?scp=84902216759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902216759&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-394296-8.00023-3

DO - 10.1016/B978-0-12-394296-8.00023-3

M3 - Chapter

SN - 9780123942968

SP - 373

EP - 394

BT - Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition

PB - Elsevier Inc.

ER -